Historical Valuation
Lyell Immunopharma Inc (LYEL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.59. The fair price of Lyell Immunopharma Inc (LYEL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：25.02
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lyell Immunopharma Inc (LYEL) has a current Price-to-Book (P/B) ratio of 1.70. Compared to its 3-year average P/B ratio of 0.73 , the current P/B ratio is approximately 132.54% higher. Relative to its 5-year average P/B ratio of 1.19, the current P/B ratio is about 43.34% higher. Lyell Immunopharma Inc (LYEL) has a Forward Free Cash Flow (FCF) yield of approximately -26.92%. Compared to its 3-year average FCF yield of -52.82%, the current FCF yield is approximately -49.04% lower. Relative to its 5-year average FCF yield of -38.58% , the current FCF yield is about -30.22% lower.
P/B
Median3y
0.73
Median5y
1.19
FCF Yield
Median3y
-52.82
Median5y
-38.58
Competitors Valuation Multiple
AI Analysis for LYEL
The average P/S ratio for LYEL competitors is 15.22, providing a benchmark for relative valuation. Lyell Immunopharma Inc Corp (LYEL.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -55.88%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LYEL
1Y
3Y
5Y
Market capitalization of LYEL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LYEL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LYEL currently overvalued or undervalued?
Lyell Immunopharma Inc (LYEL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.59. The fair price of Lyell Immunopharma Inc (LYEL) is between to according to relative valuation methord.
What is Lyell Immunopharma Inc (LYEL) fair value?
LYEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lyell Immunopharma Inc (LYEL) is between to according to relative valuation methord.
How does LYEL's valuation metrics compare to the industry average?
The average P/S ratio for LYEL's competitors is 15.22, providing a benchmark for relative valuation. Lyell Immunopharma Inc Corp (LYEL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -55.88%, this premium appears unsustainable.
What is the current P/B ratio for Lyell Immunopharma Inc (LYEL) as of Jan 09 2026?
As of Jan 09 2026, Lyell Immunopharma Inc (LYEL) has a P/B ratio of 1.70. This indicates that the market values LYEL at 1.70 times its book value.
What is the current FCF Yield for Lyell Immunopharma Inc (LYEL) as of Jan 09 2026?
As of Jan 09 2026, Lyell Immunopharma Inc (LYEL) has a FCF Yield of -26.92%. This means that for every dollar of Lyell Immunopharma Inc’s market capitalization, the company generates -26.92 cents in free cash flow.
What is the current Forward P/E ratio for Lyell Immunopharma Inc (LYEL) as of Jan 09 2026?
As of Jan 09 2026, Lyell Immunopharma Inc (LYEL) has a Forward P/E ratio of -3.10. This means the market is willing to pay $-3.10 for every dollar of Lyell Immunopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lyell Immunopharma Inc (LYEL) as of Jan 09 2026?
As of Jan 09 2026, Lyell Immunopharma Inc (LYEL) has a Forward P/S ratio of 0.00. This means the market is valuing LYEL at $0.00 for every dollar of expected revenue over the next 12 months.